Valuation : Insmed Incorporated

Market Cap 28.13B 24.2B 22.79B 20.77B 38.85B 2,676B 39.01B 270B 104B 1,364B 106B 103B 4,320B P/E 2026 *
-78.8x
P/E 2027 * 153x
Enterprise Value 27.5B 23.66B 22.28B 20.3B 37.98B 2,616B 38.13B 264B 102B 1,333B 103B 101B 4,223B EV / Sales 2026 *
15.2x
EV / Sales 2027 * 9.35x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -
1 day+3.13%
1 week+1.71%
Current month+5.73%
1 month-1.75%
3 months+30.05%
6 months-10.01%
Current year-25.99%
1 week 121.04
Extreme 121.035
130.83
1 month 117.15
Extreme 117.15
135.3
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap. Importance
8/17/26 Sell

Director

-5,000 0.0023%
8/10/26 Exercice

Chief Operating Officer

719,550 0.3320%
8/6/26 Exercice

Chief Technology Officer

81,519 0.0376%
Change 5-day change 1-year change 3-year change Capi.($)
+3.13%+1.71%-12.50%+390.48% 27.27B
-0.94%-0.71%+45.60%+103.25% 69.19B
-0.07%-3.93%+32.54%+78.50% 62.97B
-2.87%-6.43%+26.17%+11.10% 25.8B
-0.54%-5.47%-3.88%-18.31% 24.78B
-1.43%-1.89%+21.32%-19.01% 20.11B
-4.27%+3.07%+211.22%+362.48% 18.47B
-1.50%-4.63%-5.33%+506.66% 14.88B
+1.14%-0.34%+52.38%+163.82% 14.29B
+1.50%+20.14%-6.83%+1,038.96% 13.79B
Average -0.58%+1.49%+36.07%+261.79% 29.15B
Weighted average by Cap. -0.56%-0.22%+35.49%+182.07%

Financials

2026 *2027 *
Net sales 1.81B 1.55B 1.46B 1.33B 2.5B 172B 2.51B 17.35B 6.7B 87.57B 6.78B 6.64B 277B 2.89B 2.48B 2.34B 2.13B 3.99B 275B 4B 27.71B 10.71B 140B 10.84B 10.6B 443B
Net income -349M -301M -283M -258M -483M -33.24B -484M -3.35B -1.3B -16.94B -1.31B -1.28B -53.65B 217M 187M 176M 160M 300M 20.65B 301M 2.08B 805M 10.52B 815M 797M 33.32B
Net Debt -632M -544M -512M -466M -873M -60.12B -876M -6.07B -2.34B -30.63B -2.37B -2.32B -97.03B -1.16B -995M -937M -854M -1.6B -110B -1.6B -11.11B -4.29B -56.07B -4.34B -4.25B -178B
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
26-09-09 US$128.80 +3.13% 2,841,960
26-09-08 US$124.89 -1.11% 1,605,099
26-09-04 US$126.29 -0.31% 1,802,693
26-09-03 US$126.68 +0.04% 1,885,698
26-09-02 US$126.63 +4.21% 1,998,834
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
128.80USD
Average target price
200.18USD
Spread / Average Target
+55.42%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!